Azelis reports 8.2% organic growth and EUR 350m Americas impairment

Azelis reported third-quarter 2026 revenue of EUR 1.1bn, up 8.5% in constant currency, with 8.2% organic growth, and adjusted EBITA rising 14.6% to EUR 114m. Gross profit reached EUR 263m and the adjusted EBITA margin widened to 10.2%. The group also booked a EUR 350m non-cash goodwill impairment in the Americas on acquisitions made between 2021 and 2023, and it still expects positive organic adjusted EBITA growth for full-year 2026.

Key facts

Market context

Azelis is a chemical distributor and specialty ingredients formulator, meaning it buys products from producers and sells them to downstream manufacturers, often adding technical support and blending. Its portfolio spans speciality chemicals, food ingredients, industrial chemicals and life sciences ingredients. Demand is driven by end markets such as pharmaceuticals, personal care, agricultural and environmental services, lubricants and metalworking fluids, and coatings, adhesives, sealants and elastomers. For buyers, distributor performance is a read on how much product is moving through the value chain and how well specialty demand is holding up against weaker commodity cycles. Distributors earn margins on volume, mix and service rather than on raw commodity price swings, so gross profit and margin trends matter as much as headline sales. Goodwill impairments typically reflect past acquisitions that underperform expectations, which can signal a more cautious approach to deal-making in the affected region.

Source: official release on azelis.com. Summary and context written by Market Krystal.